OPINION: S&P 500 also comes to the edge of a bear market, or hints at a recession
Deep Tide TechFlow - April 7, 2013 - Futures linked to the S&P 500 fell further on Monday, dropping more than 20 percent from their all-time highs, as the US stock market's most-watched benchmark index is on the verge of confirming a bear market, according to Golden Ten Data. Futures on the Dow Jones Industrial Stock Average are also down 20 per cent from their all-time highs, while the Nasdaq confirmed it was in a bear market last week as fears of a recession in the wake of Trump's sweeping tariffs battered global stock markets.
Under a widely used definition, an index is confirmed to be in a bear market if it closes more than 20 per cent below its all-time closing high. The last time the S&P 500 confirmed it was in bear market territory was in June 2022, when investors worried about whether the Federal Reserve would be able to curb post-epidemic inflation without triggering a recession. Bear markets typically lead to recessions and last until investors believe the worst stages of a recession are behind them. Nine of the 12 bear markets since 1948 have been accompanied by recessions, according to investment research firm CFRA.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
This Isn’t a Crypto Crash. Fed Hike Bets Are Hitting Everything

The "chip dollar" is on the rise! Deutsche Bank: Asia's chip trade surplus flows into US stocks, becoming a new pillar for the dollar
Deutsche Bank believes that the continuously expanding chip trade surplus in Asia is becoming a supporting force for the US dollar, as related profits are increasingly being reinvested into the US stock market.

Roche's (RHHBY.US) new breast cancer drug Wilserdly approved by FDA: Analysts predict peak annual sales could reach up to $14.5 billion
Roche's (RHHBY.US) new oral breast cancer drug has been approved by U.S. regulators, paving the way for this medication, which the pharmaceutical company hopes will transform the treatment of the disease.
